AstraZeneca/£AZN
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About AstraZeneca
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Ticker
£AZN
Sector
Primary listing
LSE
Industry
Pharmaceuticals
Headquarters
Employees
94,300
ISIN
GB0009895292
Website
AstraZeneca Metrics
BasicAdvanced
£164B
28.66
£3.68
0.18
£2.46
2.33%
Price and volume
Market cap
£164B
Beta
0.18
52-week high
£132.18
52-week low
£95.74
Average daily volume
2.1M
Dividend rate
£2.46
Financial strength
Current ratio
0.897
Quick ratio
0.694
Long term debt to equity
67.922
Total debt to equity
77.112
Dividend payout ratio (TTM)
63.60%
Interest coverage (TTM)
10.16%
Profitability
EBITDA (TTM)
13,542.343
Gross margin (TTM)
82.44%
Net profit margin (TTM)
14.14%
Operating margin (TTM)
24.75%
Effective tax rate (TTM)
16.26%
Revenue per employee (TTM)
£429,750
Management effectiveness
Return on assets (TTM)
8.16%
Return on equity (TTM)
19.79%
Valuation
Price to earnings (TTM)
28.657
Price to revenue (TTM)
4.015
Price to book
3.99
Price to tangible book (TTM)
-9.27
Price to free cash flow (TTM)
24.01
Free cash flow yield (TTM)
4.16%
Free cash flow per share (TTM)
439.48%
Dividend yield (TTM)
2.33%
Growth
Revenue change (TTM)
15.48%
Earnings per share change (TTM)
22.71%
3-year revenue growth (CAGR)
9.84%
10-year revenue growth (CAGR)
7.72%
3-year earnings per share growth (CAGR)
90.42%
10-year earnings per share growth (CAGR)
17.24%
3-year dividend per share growth (CAGR)
2.60%
10-year dividend per share growth (CAGR)
1.02%
What the Analysts think about AstraZeneca
Analyst ratings (Buy, Hold, Sell) for AstraZeneca stock.
Bulls say / Bears say
AstraZeneca's triple-combination inhaler, Breztri Aerosphere, achieved all main objectives in late-stage clinical trials for treating uncontrolled asthma, potentially expanding its market share in respiratory treatments. (reuters.com)
The company raised its 2024 sales and profit forecast due to strong demand for cancer and rare disease medicines, indicating robust growth in key therapeutic areas. (reuters.com)
AstraZeneca plans to invest $2.5 billion in a new research center in Beijing, reflecting confidence in the Chinese market and commitment to expanding its R&D capabilities. (fastbull.com)
AstraZeneca's first-quarter revenues fell short of analyst expectations, leading to a share price decline of more than 4%, raising concerns about its financial performance. (reuters.com)
The company faces potential fines of up to $4.5 million in China for unpaid import taxes, which could impact its financials and operations in a key market. (reuters.com)
Despite raising its 2024 outlook, AstraZeneca's shares have fallen nearly 6% this year due to concerns over its Chinese business amid investigations, affecting investor confidence. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 22 May 2025.
AstraZeneca Financial Performance
Revenues and expenses
AstraZeneca Earnings Performance
Company profitability
AstraZeneca News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for AstraZeneca stock?
AstraZeneca (AZN) has a market cap of £164B as of June 20, 2025.
What is the P/E ratio for AstraZeneca stock?
The price to earnings (P/E) ratio for AstraZeneca (AZN) stock is 28.66 as of June 20, 2025.
Does AstraZeneca stock pay dividends?
Yes, the AstraZeneca (AZN) stock pays dividends to shareholders. As of June 20, 2025, the dividend rate is £2.456 and the yield is 2.33%. AstraZeneca has a payout ratio of 63.6% on a trailing twelve-month basis.
When is the next AstraZeneca dividend payment date?
The next AstraZeneca (AZN) dividend payment date is unconfirmed.
What is the beta indicator for AstraZeneca?
AstraZeneca (AZN) has a beta rating of 0.18. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.